BIOPOR Bioporto A/S

BioPorto A/S - Annual General Meeting

BioPorto A/S - Annual General Meeting

April 14, 2020

Announcement no. 9

BioPorto A/S - Annual General Meeting

Today, BioPorto A/S held its Annual General Meeting during which the report on the Company’s activities was reviewed and the 2019 Annual Report was adopted. The proposed profit/loss allocation was also adopted and discharge of liability was granted to the Board of Directors and the Executive Management. Finally, the remuneration for the Board of Directors was approved.

Thomas Magnussen, Torben A. Nielsen, Kirsten Aarup Drejer, Christopher Lindop and Michael S. Singer were re-elected as members of the Board of Directors. Immediately following the Annual General Meeting, the Board of Directors elected Thomas Magnussen as its Chairman and Torben A. Nielsen as its Vice Chairman. 

The proposals from the Board of Directors under item 6 of the agenda were all adopted, and included: a) Amending the Articles of Association regarding shareholders’ notification of attendance for a general meeting, b) Amending the standard agenda for the Annual General Meeting in Article 8 in the Articles of Association, c) Renewing the authorization to issue warrants for up to DKK 2,500,000 following decision by the Board of Directors to amend its original proposal of up to DKK 6,600,000 shares, d) Approving the Company’s revised Remuneration Policy and e) Authorization to the Chairman of the general meeting.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.

Hellerup, April 14, 2020

BioPorto A/S

The Board of Directors

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

EN
14/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

BioPorto indsender anmodning om FDA pre‑submission for amerikansk voks...

BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off 31. marts, 2026Meddelelse no. 6 BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off KØBENHAVN, DANMARK, 31. marts, 2026 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH: BIOPOR) meddelte i dag, at de formelt har indsendt deres FDA Pre-submission pakke til den amerikanske Food and Drug Administration (FDA). Dette markerer en vigtig regulatorisk milepæl for Selskabet ...

 PRESS RELEASE

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submissio...

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis March 31, 2026Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced that it has formally submitted its FDA pre‑submission package to the U.S. Food and Drug Administration (FDA). This marks an important regulatory milestone for the Company and follows the positive preliminary an...

 PRESS RELEASE

Indkaldelse til ordinær generalforsamling i BioPorto A/S

Indkaldelse til ordinær generalforsamling i BioPorto A/S 26. marts 2026Selskabsmeddelelse nr. 5 Indkaldelse til ordinær generalforsamling i BioPorto A/S Bestyrelsen indkalder hermed til ordinær generalforsamling i BioPorto A/S ("BioPorto" eller "Selskabet"), som afholdes: 24. april 2026 kl. 15.00på Selskabets adresseTuborg Havnevej 15, st., 2900 Hellerup, Danmark DAGSORDEN: PUNKT 1 - BERETNING OM SELSKABETS VIRKSOMHED I DET FORLØBNE ÅR Bestyrelsen foreslår, at bestyrelsens beretning om Selskabets virksomhed i det forløbne år tages til efterretning. PUNKT 2 – FREMLÆGGELSE AF ÅRSRAPP...

 PRESS RELEASE

Notice convening the Annual General Meeting in BioPorto A/S

Notice convening the Annual General Meeting in BioPorto A/S 26 March 2026Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: 24 April 2026 at 3.00 p.m. (CEST)at the Company’s addressTuborg Havnevej 15, st., DK-2900 Hellerup, Denmark AGENDA: ITEM 1 - REPORT ON THE COMPANY’S ACTIVITIES DURING THE PAST YEAR The Board of Directors proposes that the Board's report on the Company’s activities for the past year be noted. ITEM 2 – PRESENT...

 PRESS RELEASE

BioPorto annoncerer Årsrapporten for 2025

BioPorto annoncerer Årsrapporten for 2025 26. marts 2026Meddelelse nr. 04                                                                                                                                                                                                BioPorto annoncerer årsrapporten for 2025 København, Danmark, 26. marts 2026 (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller selskab) (CPH:BIOPOR) offentliggjorde i dag de finansielle resultater for året 2025. De finansielle resultater for 2025 bekræfter de foreløbige, ureviderede finansielle tal for 202...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch